Paracetamol ALF: pH <7.30 or all three: INR >6.5, creatinine >300 µmol/L, grade III/IV encephalopathy
Non-paracetamol ALF: INR >6.5 or any 3 of: unfavourable aetiology, jaundice-to-encephalopathy interval >7 days, bilirubin >300 µmol/L, INR >3.5, age <10 or >40 years
GCC Note: MASLD-related cirrhosis is the fastest-growing indication across GCC centres, mirroring the high prevalence of metabolic syndrome and type 2 diabetes in the region.
🚫 Contraindications
Absolute Contraindications
Active extrahepatic malignancy (not in remission)
Active substance misuse (alcohol or illicit drugs) — current, not adequately treated
Severe uncontrolled psychiatric illness precluding compliance
Documented persistent non-compliance with medical treatment
Uncontrolled sepsis or active untreated infection
Severe irreversible cardiopulmonary disease (poor surgical candidacy)
Advanced AIDS (uncontrolled HIV — well-controlled HIV is now a relative CI)
GCC LDLT: Islamic jurisprudence permits living organ donation. KFSH&RC in Riyadh operates one of the world's largest and most experienced LDLT programmes — a regional centre of excellence. LDLT constitutes the majority of adult liver transplants performed in Saudi Arabia.
Split Liver Transplant: A single deceased donor liver is surgically divided — the right lobe/larger portion goes to an adult recipient; the left lateral segment to a paediatric recipient. This maximises one organ to benefit two patients and is especially valuable in paediatric organ shortage.
HCC within Milan criteria: MELD exception points (typically equivalent MELD 22 at listing, increase every 3 months if no transplant) — prevents tumour progression disadvantaging patients against non-HCC candidates
Hepatopulmonary syndrome (HPS): MELD exception — severe hypoxaemia (PaO₂ <60 mmHg) from intrapulmonary shunting resolves after transplant
Portopulmonary hypertension: exception if mPAP responsive to vasodilator therapy
Recurrent encephalopathy / refractory ascites: Some allocation committees grant additional points
CVP monitoring: fluid status guidance — target 5–8 cmH₂O
PA catheter / advanced haemodynamic monitoring: if pre-existing cardiopulmonary compromise or haemodynamic instability
Ventilator management: lung-protective settings, early weaning protocol — aim extubation within 6–12 hours if haemodynamically stable
Temperature: active warming — coagulopathy worsens with hypothermia
Vasopressors: noradrenaline first-line for hepatic artery vasospasm avoidance
Nursing Observations
Hourly urine output: target >0.5 mL/kg/h — best bedside indicator of graft function recovery (reflects hepatic lactate clearance and haemodynamics)
Biliary drain / T-tube: monitor colour (golden bile = healthy graft), volume (200–700 mL/day typical), consistency. Dark or absent bile = concern. Record accurately every shift.
Glucose: 1-2 hourly — liver produces glucose; hypoglycaemia in early phase = poor graft function
🚨 Early Complications — Recognition & Response
Primary Non-Function (PNF) — Graft fails to function immediately after transplant. Signs: INR not improving (often rising), LFTs extremely elevated, persistent hypoglycaemia, encephalopathy, high lactate, no bile. Action: emergency re-listing for re-transplant. Time-critical — graft must be replaced urgently. Incidence ~2–5%.
Hepatic Artery Thrombosis (HAT) — Most common early vascular complication (3–5%). Hepatic artery supplies the biliary tree — thrombosis causes biliary necrosis and graft loss. Clinical features: abrupt rise in LFTs/AST (sometimes thousands), biliary leak, fever, sepsis. Diagnosis: Doppler USS (absent hepatic artery flow) — should be performed within 24h post-transplant as baseline and if any clinical concern. Management: urgent surgical thrombectomy or re-transplant.
Portal Vein Thrombosis (PVT) — Less common. Presents with graft dysfunction, ascites, variceal bleeding. Doppler USS diagnosis. Anticoagulation or thrombectomy depending on timing/severity.
Biliary Complications — Most common overall complication (10–30%). Types: bile leak (early — T-tube site or anastomosis), biliary stricture (anastomotic or ischaemic from DCD/HAT). T-tube bile leak: bile in drain or peritoneal signs. Management: ERCP with stenting, or surgical repair. Biliary drains require careful daily care: note colour, volume, consistency; avoid kinking.
Acute Rejection — Acute cellular rejection (ACR) is most common (20–40%). Occurs typically day 5–30. Signs: rising LFTs (AST/ALT/ALP), fever, graft tenderness, malaise. Diagnosis: liver biopsy (Banff grading). Treatment: high-dose IV methylprednisolone 500 mg/day × 3 days. Steroid-resistant: OKT3 or ATG (antithymocyte globulin).
Complication
Key Clinical Indicator
Diagnostic Tool
Priority
Primary Non-Function
INR rising, hypoglycaemia, no bile
LFTs, lactate, glucose
Immediate
Hepatic Artery Thrombosis
Abrupt LFT surge, no bile
Doppler USS
Urgent
Biliary Leak
Bile in drain, peritonism
ERCP / CT
Urgent
Acute Cellular Rejection
LFT rise days 5–30
Liver biopsy
Timely
Post-operative haemorrhage
Drain output blood, Hb drop, hypotension
Surgical review / CT angiogram
Immediate
💊 Immunosuppression Initiation (ICU Phase)
Tacrolimus initiated within 24–72 hours post-transplant (delayed if renal impairment — use basiliximab induction bridge)
IV methylprednisolone intraoperatively and post-operatively, then transition to oral prednisolone
MMF (mycophenolate mofetil) commenced once oral route established and haemodynamically stable
Tacrolimus trough target: 10–15 ng/mL in first month (higher early to cover rejection risk)
Levels measured daily in ICU — adjust dose accordingly; consult pharmacist/transplant team
💊 Standard Triple Immunosuppression Regimen
Drug
Class
Mechanism
Key Side Effects
Monitoring
Tacrolimus (Prograf / Advagraf)
Calcineurin inhibitor (CNI)
Inhibits calcineurin → blocks IL-2 production → T-cell suppression
Grapefruit juice (CYP3A4 inhibition) — advise patients to avoid
Drugs that DECREASE Tacrolimus Levels (rejection risk)
Rifampicin: potent CYP3A4/P-gp inducer — markedly decreases tacrolimus levels. Use alternative anti-TB agents where possible; if unavoidable, tacrolimus dose may need 5–10× increase with very close monitoring.
St John's Wort (herbal) — advise patients to avoid all herbal remedies without checking
GCC Relevance: TB is endemic in many donor/recipient population countries. Rifampicin interactions with tacrolimus are critically important — always check with transplant pharmacist before initiating any new medication.
Bacterial: broad-spectrum IV antibiotics peri-operatively (cefazolin or piperacillin/tazobactam ± metronidazole). Selective bowel decontamination in some centres.
Fungal: fluconazole or micafungin for 4–6 weeks post-transplant. Voriconazole/posaconazole if high-risk (e.g. prior Aspergillus).
CMV: Ganciclovir IV (aciclovir-resistant) → oral valganciclovir for 3–6 months prophylaxis. Duration based on donor/recipient CMV serostatus (D+/R- highest risk).
PCP: Co-trimoxazole (trimethoprim-sulfamethoxazole) for 6–12 months post-transplant. Dapsone if sulfa allergy.
HSV/VZV: Aciclovir prophylaxis for 3 months minimum.
Viral Surveillance
CMV PCR: weekly for first 3 months, then monthly. CMV disease: fever, cytopenias, tissue-invasive (hepatitis, pneumonitis, colitis). Treat with IV ganciclovir.
Vaccination Post-Transplant: All inactivated/subunit vaccines are safe and recommended — influenza (annual), pneumococcal, hepatitis A/B, COVID-19. Live attenuated vaccines are absolutely contraindicated post-transplant (MMR, varicella, live influenza, yellow fever).
🔄 Rejection — Chronic & Late
Chronic Rejection — Ductopenic
Also called vanishing bile duct syndrome (VBDS)
Progressive loss of intrahepatic bile ducts over months-years
Monitoring: fasting glucose and HbA1c at 1, 3, 6, 12 months then annually
Management: insulin initially in early post-transplant (steroid effect fluctuates), transition to oral agents as steroids taper. Avoid metformin in renal impairment.
Tacrolimus switch to cyclosporin reduces NODAT risk (though cyclosporin has other side effects)
BP target: <130/80 mmHg. CCBs or ACEi/ARB first-line.
Statin therapy: pravastatin or fluvastatin preferred (low CYP3A4 interaction with tacrolimus)
Renal Dysfunction
Tacrolimus nephrotoxicity leads to CKD in up to 20% at 5 years
eGFR monitoring every 3 months
Switch to everolimus or sirolimus (mTOR inhibitors) + reduced tacrolimus if CKD progressing — renal-sparing strategy. Note: everolimus increases rejection risk if tacrolimus stopped completely.
Avoid nephrotoxic drugs: NSAIDs, aminoglycosides, contrast without pre-hydration
🎗️ De Novo Malignancy Post-Transplant
Skin Cancer (SCC) 100× general population risk. Squamous cell carcinoma > basal cell carcinoma. Sun protection counselling, annual dermatology review, consider acitretin for high-risk. Melanoma risk also elevated.
Driving: typically cleared at 6–12 weeks if no neurological issues and off high-dose opioids
Return to work: light desk work 3–6 months; physical labour 6–12 months
Exercise: encourage progressive return to activity — improves metabolic outcomes and QoL
Diet: balanced, avoid raw seafood (Vibrio risk in immunosuppressed), avoid grapefruit, limit alcohol entirely
Dental visits: antibiotic prophylaxis policy varies — check with transplant team before invasive procedures
Sexual Health & Pregnancy
Sexual function often improves significantly post-transplant (resolution of hypogonadism from cirrhosis)
Pregnancy post-transplant: advise delay 1–2 years post-transplant for stable graft function and reduced immunosuppression
Tacrolimus is generally considered safe in pregnancy (category C — monitor fetal growth, prematurity risk)
MMF is teratogenic — must be discontinued before conception, switched to azathioprine
Close multidisciplinary monitoring (transplant + obstetrics): monthly tacrolimus levels in pregnancy as levels change with gestational physiology
Psychological Support: Depression and anxiety are common post-transplant. Ongoing psychological support, peer support groups, and transplant coordinator accessibility are essential components of long-term care.
🌍 GCC Context — Transplant Landscape
Regional Centres & LDLT Leadership
KFSH&RC Riyadh: King Faisal Specialist Hospital & Research Centre — one of the world's highest-volume LDLT programmes; regional centre of excellence for adult and paediatric liver transplantation
Living donor liver transplantation predominates over deceased donor transplantation in Saudi Arabia due to historically limited deceased donor organ availability
Saudi Centre for Organ Transplantation (SCOT) oversees national transplant programme, waitlists, and allocation policy
UAE: Sheikh Shakhbout Medical City (SSMC) and Cleveland Clinic Abu Dhabi expanding liver transplant programmes
Kuwait, Qatar, Bahrain: mostly refer complex cases to Saudi Arabia or Jordan (King Hussein Medical Centre)
Islamic Jurisprudence & Organ Donation
Brain death as legal death: accepted by the majority of Islamic scholars and fatwa-issuing bodies in GCC (including Saudi Arabia's Council of Senior Scholars), permitting DBD donation
Islamic Fiqh Academies have issued fatwas permitting living and deceased organ donation as an act of charity (sadaqah jariyah) when conditions of no harm to donor and consent are met
Religious opposition to DCD transplantation is more common as death timing is less clear — most GCC centres focus on DBD and LDLT
Family consent culture is important — culturally sensitive counselling for donation discussions with families
MASLD Epidemic: Metabolic-associated steatotic liver disease (MASLD, formerly NAFLD/NASH) is surpassing viral hepatitis as the primary indication for liver transplantation in GCC, driven by high rates of obesity, T2DM, and sedentary lifestyle.
📚 High-Yield DHA/DOH/SCFHS Exam Points
MELD score formula and what each component represents; MELD ≥15 = transplant threshold
Milan criteria for HCC: ≤1 lesion ≤5cm OR ≤3 lesions each ≤3cm, no vascular invasion/metastasis
1. A patient on day 7 post liver transplant develops fever, malaise, and liver function tests show AST 380 U/L (rising from 90 U/L). What is the most likely diagnosis and the gold standard investigation?
A. Hepatic artery thrombosis — Doppler USS
B. Acute cellular rejection — liver biopsy
C. CMV hepatitis — CMV PCR
D. Primary non-function — clinical assessment
Acute cellular rejection (ACR) most commonly occurs between day 5–30 post-transplant. It presents with rising transaminases, fever, and graft tenderness. Gold standard diagnosis is liver biopsy (Banff grading). Treatment is IV methylprednisolone 500 mg/day for 3 days.
2. A patient's tacrolimus trough level is 18 ng/mL at 3 weeks post liver transplant. They report tremor and new-onset confusion. What is the most appropriate action?
A. Increase tacrolimus dose — rejection risk
B. Perform liver biopsy immediately
C. Reduce tacrolimus dose and notify transplant team — supra-therapeutic level with neurotoxicity
D. Reassure patient — tremor is normal post-transplant
The target trough for early phase (<1 month) is 10–15 ng/mL. A level of 18 ng/mL is supra-therapeutic. Tremor and confusion are classic signs of tacrolimus neurotoxicity (can progress to PRES). The dose should be reduced and the transplant team urgently notified. MRI brain if PRES suspected.
3. A patient is 2 hours post liver transplant in ICU. Biliary drain output is dark brown with minimal volume, lactate is rising (4.2 mmol/L), glucose is 2.8 mmol/L, and INR is 3.1. What complication must be urgently considered?
A. Biliary leak
B. Acute cellular rejection
C. CMV hepatitis
D. Primary non-function (PNF)
Primary non-function (PNF) presents immediately post-transplant with: absent or poor quality bile, rising lactate (impaired hepatic lactate clearance), hypoglycaemia (liver not producing glucose), non-improving/worsening INR, and encephalopathy. This is a surgical emergency requiring urgent re-transplant listing.
4. Which of the following post-transplant vaccines is absolutely contraindicated?
A. Annual inactivated influenza vaccine
B. Pneumococcal polysaccharide vaccine (PPV23)
C. MMR (measles-mumps-rubella) vaccine
D. Hepatitis B vaccine (recombinant)
Live attenuated vaccines (MMR, varicella/zoster live, oral typhoid, yellow fever, live intranasal influenza) are absolutely contraindicated post-transplant due to risk of vaccine-strain infection in an immunosuppressed host. All inactivated, subunit, or recombinant vaccines are safe and recommended.
5. A liver transplant nurse notes that a patient who has been stable for 8 months on tacrolimus and MMF is starting rifampicin for active pulmonary TB. What is the primary concern?
A. Rifampicin will increase tacrolimus to toxic levels
B. Rifampicin is a CYP3A4 inducer that will markedly decrease tacrolimus levels, risking rejection
C. MMF will reduce rifampicin efficacy
D. No significant drug interaction exists
Rifampicin is a potent CYP3A4 and P-glycoprotein inducer. It markedly decreases tacrolimus bioavailability and blood levels, placing the patient at high risk of acute rejection. Tacrolimus dose may need to be increased 5–10 fold. Intensive trough monitoring is essential. Always consult transplant pharmacist immediately. This is a critical drug interaction especially relevant in GCC due to TB prevalence.
6. What is the most common early vascular complication after liver transplantation and how is it diagnosed?
A. Portal vein thrombosis — CT angiogram
B. Hepatic artery thrombosis — Doppler ultrasound
C. Inferior vena cava stenosis — venography
D. Hepatic vein thrombosis — MRI
Hepatic artery thrombosis (HAT) is the most common early vascular complication (3–5%). The hepatic artery exclusively supplies the biliary tree — thrombosis causes biliary necrosis and can lead to graft loss. Doppler ultrasound is the first-line, non-invasive diagnostic tool. A baseline Doppler should be obtained within 24 hours of transplant, and repeated urgently if clinical concern arises.
7. A female liver transplant patient (3 years post-transplant, stable) wishes to become pregnant. Which immunosuppressant must be changed before conception?
A. Tacrolimus — switch to cyclosporin
B. Prednisolone — stop immediately
C. Mycophenolate mofetil (MMF) — switch to azathioprine
D. No changes needed — all transplant medications are safe in pregnancy
MMF (mycophenolate mofetil / CellCept) is teratogenic — associated with miscarriage and congenital malformations (microtia, cleft lip/palate, limb defects). It must be discontinued and switched to azathioprine at least 6 weeks before conception. Tacrolimus is considered relatively safe in pregnancy (monitor levels monthly as they change with gestational physiology). Prednisolone at low doses is also acceptable.
8. A liver transplant recipient has MELD 28 and hepatocellular carcinoma with a single 4.5 cm nodule and no vascular invasion. Is this patient within Milan criteria and eligible for transplant?
A. No — single lesion must be ≤3 cm for Milan criteria
B. Yes — single lesion ≤5 cm without vascular invasion meets Milan criteria
C. Yes — but only if MELD exceeds 30
D. No — HCC is an absolute contraindication to liver transplant
Milan criteria for HCC: single lesion ≤5 cm OR up to 3 lesions each ≤3 cm, with no macrovascular invasion and no extrahepatic metastases. A single 4.5 cm lesion meets these criteria. These patients receive MELD exception points on the waiting list to reflect tumour progression risk. Transplant within Milan criteria provides 5-year survival comparable to non-HCC transplants (~70%).
9. A post-transplant patient has EBV PCR rising from undetectable to 50,000 copies/mL over 6 weeks. They are on triple immunosuppression. What is the most important initial management step?
A. Start ganciclovir immediately
B. Start rituximab immediately
C. Reduce immunosuppression and investigate for PTLD
D. Repeat EBV PCR in 4 weeks and reassess
Rising EBV PCR in a transplant patient signals risk of PTLD (post-transplant lymphoproliferative disorder), a B-cell malignancy. The first and most important step is reducing immunosuppression — this can allow immune-mediated control of EBV-driven B-cell proliferation. Investigations include CT PET scan, lymph node biopsy to confirm PTLD. If PTLD confirmed: rituximab (anti-CD20) and/or chemotherapy. Ganciclovir is for CMV, not primary treatment of EBV/PTLD.
10. In the context of GCC nursing practice, which of the following best describes the Islamic jurisprudential position on living organ donation for liver transplantation?
A. Unanimously prohibited by all Islamic scholars as mutilation of the body
B. Permitted only in cases where the donor is a first-degree relative
C. Permitted by the majority of Islamic scholars and fatwa bodies when conditions of informed consent and no disproportionate harm to the donor are met
D. Prohibited for living donation but permitted for all forms of deceased donation
The Islamic Fiqh Academy and the Council of Senior Scholars in Saudi Arabia have issued fatwas permitting living organ donation as an act of altruism (saving a life — ihya al-nafs), provided: the donor gives free and informed consent, the donation does not pose disproportionate risk, and no financial coercion is involved. Brain death is accepted as legal death by most GCC scholarly bodies, permitting DBD donation. This is why LDLT thrives in GCC countries.
🧮 Interactive: Tacrolimus Level Interpreter
Tacrolimus Trough Level Interpreter
Enter the patient's tacrolimus trough level and clinical details to receive interpretation and dose guidance. This tool is for educational purposes — always consult the transplant team for clinical decisions.